Clinical trials - Press Releases

Date	Title	Company
09-Nov-2023	HUTCHMED Announces that Takeda Receives U.S. FDA Approval of FRUZAQLA™ (fruquintinib) for Previously Treated Metastatic Colorectal Cancer	HUTCHMED
07-Nov-2023	Ground-breaking treatment for Alcohol Use Disorder shown to halve alcohol consumption amongst heavy drinkers in three months at phase II: a new hope for patients	Kinnov Therapeutics
06-Nov-2023	Zibotentan/dapagliflozin combination demonstrated significant albuminuria reduction in patients with chronic kidney disease and proteinuria in ZENITH-CKD Phase IIb trial	AstraZeneca
02-Nov-2023	Novotech Releases In-Depth 2023 Global Clinical Trial Landscape Reports on Hemophilia and Primary Biliary Cholangitis	Novotech
01-Nov-2023	Anaveon announces presentation of ANV600 preclinical data supporting combination therapy with therapeutic PD-1 inhibitors	Anaveon
31-Oct-2023	Nouscom’s Off-the-Shelf Cancer Vaccine, NOUS-209, Shows Potential to ‘Intercept’ Cancer in Subjects with Lynch Syndrome	Nouscom
31-Oct-2023	LEO Pharma announces positive outcome of DELTA 3 open-label extension trial of delgocitinib cream in the treatment of adults with moderate to severe chronic hand eczema (CHE)	LEO Pharma
31-Oct-2023	Elligo and Avallano Launching Patient-First, AI-Powered Clinical Trials Ecosystem	Elligo Health Research®
26-Oct-2023	Phastar Offers Pro Bono Support to Medicines Development for Global Health	Phastar
26-Oct-2023	IDP Pharma announces first patient dosed in a Phase 1/2 Clinical Trial of IDP-121, a direct cMyc protein inhibitor and degrader	IDP Pharma
26-Oct-2023	GALDERMA PHASE III DATA PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE: FULL OLYMPIA 2 TRIAL RESULTS DEMONSTRATE NEMOLIZUMAB’S RAPID ONSET OF ACTION IN PRURIGO NODULARIS PATIENTS	Galderma
26-Oct-2023	Immunocore presents three-year overall survival data from the KIMMTRAK Phase 3 trial	Immunocore
26-Oct-2023	Kancera reports that the phase I study of KAND145 has received regulatory approval	Kancera AB
26-Oct-2023	Landmark Phase 3 MARIPOSA Study Shows RYBREVANT®▼(amivantamab) Plus Lazertinib Resulted in 30 Percent Reduction in Risk of Disease Progression or Death Compared to Osimertinib in Patients with EGFR-Mutated Non-Small Cell Lung Cancer	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Phase 3 MARIPOSA-2 Study Shows RYBREVANT®▼(amivantamab) Plus Chemotherapy Given with or without Lazertinib Reduced Risk of Disease Progression or Death by 56 and 52 Percent Respectively in Patients with EGFRMutated Non-Small Cell Lung Cancer who Progressed on or after Osimertinib	Janssen Pharmaceutical Companies of Johnson & Johnson
26-Oct-2023	Oxford BioTherapeutics Announces Partner Boehringer Ingelheim Dosed First Patient in Phase 2 Trial with BI 764532 in Small Cell Lung Cancer and other Neuroendocrine Cancers	Oxford BioTherapeutics
26-Oct-2023	PharmaKure submits MHRA CTA for Phase 2a Clinical Trial of PK051 in patients with mild cognitive impairment	PharmaKure
24-Oct-2023	NKGen Biotech Announces FDA Clearance of Investigational New Drug Application for SNK01 NK Cell Therapy to Treat Alzheimer’s Disease	NKGen Biotech
24-Oct-2023	ImmunOs Therapeutics Presents Overview of Phase 1a/b Trial of Lead Compound IOS-1002	ImmunOs Therapeutics
19-Oct-2023	Avance Clinical Invited to Brief 45 Korean Biotechs on Their GlobalReady Drug Development Pathway from Korea and Australia to the US	Avance Clinical